The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 02, 2002

Filed:

Mar. 01, 2001
Applicant:
Inventors:

David Reginald Adams, Wokingham, GB;

Jonathan Mark Bentley, Wokingham, GB;

Jonathan Richard Anthony Roffey, Wokingham, GB;

Corinna Dagmar Bodkin, Wokingham, GB;

Howard Langham Mansell, Wokingham, GB;

Ashley Roger George, Wokingham, GB;

Ian Anthony Cliffe, Wokingham, GB;

Assignee:

Vernalis Research Limited, Wokingham, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 3/1437 ; C07D 4/7104 ;
U.S. Cl.
CPC ...
A61K 3/1437 ; C07D 4/7104 ;
Abstract

A chemical compound of formula (I), wherein R to R are independently selected from hydrogen and alkyl; R is selected from hydrogen, alkyl, alkoxy, formyl and cyano; X is selected from N and C—R ; X is selected from N and C—R ; X is selected from N and C—R ; X is selected from N and C—R ; wherein at least one of X , X , X and X is N; and R to R are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus; and sleep apnea, and particularly for the treatment of obesity.


Find Patent Forward Citations

Loading…